fdaheadlines.com
PTC Therapeutics Inc. (NASDAQ:PTC) Report Revenue Of $86.3 In Q4 Driven By Sales Of Emflaza And Translarna - FDA Headlines
PTC Therapeutics Inc. (NASDAQ:PTC) lost 1.3% in the last trading sessions to close at $33.42 at the back of the company announcing financial results for Q4 and FY2018 as well as providing a business update. FY2018 financial results and updates The company had total revenue of $86.3 in the Q42018 with revenue for FY2018 being …